Masculinizing Hormone Therapy
Gender-Affirming Testosterone for Transmasculine and Nonbinary People, Goals, Frameworks, and Models of Care
Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Off-label (no FDA testosterone product is labeled for gender-affirming care; use is supported by major clinical guidelines)
- WADA
- Prohibited in sport (S1 Anabolic Agent), therapeutic-use context differs entirely from athletic doping
Reference only. Not medical advice.
This is something to take to a clinician. The Atlas can tell you what is known about masculinizing hormone therapy in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Gender-affirming testosterone (masculinizing hormone therapy, or GAHT/MHT) is the use of testosterone to induce male secondary sex characteristics in transmasculine and some nonbinary people whose gender differs from the female sex they were assigned at birth. It is clinically distinct from hypogonadism TRT: the goal is intentional virilization toward a typical male physiological range (often ~320-1000 ng/dL), not restoration of a deficient male's prior baseline. Two major frameworks govern care: the WPATH Standards of Care Version 8 (SOC-8, 2022) and the Endocrine Society's 2017 clinical practice guideline (lead author Wylie Hembree). Care is delivered through either an assessment model (mental-health evaluation preceding hormones) or an informed-consent model (capacity-based consent without a gatekeeping diagnosis), the latter now widespread in US clinics.
A clinically distinct, guideline-supported use of testosterone, masculinization toward a target male physiological range, not 'optimization.'
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
- Gender incongruence / dysphoria
- Persistent, well-documented incongruence between gender identity and sex assigned at birth, per WPATH SOC-8 and Endocrine Society criteria
- Capacity to consent
- Ability to make an informed decision and to consent to treatment
- Managed comorbidities
- Reasonable control of co-existing medical and mental-health conditions that could be exacerbated
How it works
Exogenous testosterone acts on the androgen receptor across target tissues to drive virilization, and is partly converted by 5-alpha-reductase to dihydrotestosterone (DHT, a more potent androgen in skin and hair follicles) and by aromatase to estradiol. Supraphysiological-for-natal-female testosterone levels suppress the hypothalamic-pituitary-gonadal axis via negative feedback, reducing LH and FSH, suppressing ovarian estrogen production and ovulation, and typically inducing amenorrhea. The clinical aim is steady androgen exposure sufficient to masculinize while keeping levels within a typical male physiological window.
Why this is not 'TRT' and not 'optimization'
Hypogonadism TRT restores a male patient to his own prior physiological baseline after a documented deficiency. Gender-affirming testosterone deliberately raises androgens far above a natal female's baseline to produce a new phenotype. The endpoint is masculinization, judged by patient goals and physical change, not by correcting a number on a deficiency panel. This also separates it cleanly from the consumer 'testosterone optimization' culture, which markets supraphysiological aspiration to men who are not deficient. Gender-affirming care, by contrast, is bounded by guidelines that target a normal male range and monitor for the same risks (erythrocytosis, lipids) rather than chasing ever-higher numbers.
Safety in detail
This intervention involves significant and partly irreversible physiological effects and requires evaluation and monitoring by a qualified physician. Self-administration of testosterone without medical oversight carries documented health risks including erythrocytosis and unmonitored cardiovascular and metabolic changes.
What it does to fertility
Testosterone suppresses ovulation and typically induces amenorrhea, but is NOT a reliable contraceptive. Effects on long-term fertility are incompletely characterized; many people resume ovulation after stopping. Fertility-preservation counseling (oocyte/embryo cryopreservation) is recommended before initiation per both WPATH SOC-8 and the Endocrine Society.
What has to be monitored
The bloodwork this needs, and the reason it belongs with a clinician rather than a website.
- Total testosterone (titrated to a typical male range)
- Hematocrit / hemoglobin (erythrocytosis surveillance)
- Lipid panel
- Periodic clinical assessment of virilization and symptoms
- Site-specific cancer screening per retained organs (cervical, etc.)
What people get wrong
Often saidGender-affirming T is just TRT for women
ActuallyIt is not. TRT restores a deficient male to his own baseline; gender-affirming testosterone intentionally masculinizes a natal-female body toward a male range. The targets, goals, and counseling differ fundamentally, even though monitoring overlaps.
Often saidHormones are handed out with no evaluation
ActuallyUnder both the assessment and informed-consent models, clinicians confirm decision-making capacity, review risks and irreversibility, screen relevant comorbidities, and counsel on fertility before initiating. Informed consent is a documented clinical process, not the absence of one.
Who profits, and who pushes back
Endocrine Society guideline panel
Stress that most masculinizing effects rest on low-quality evidence and that long-term cardiovascular, bone, and cancer outcome data in transmasculine people remain sparse.
Critics of the informed-consent model
Argue that minimizing mental-health assessment before hormones may underserve people with unaddressed comorbidities, while proponents counter that gatekeeping creates harmful barriers.
Evidence-synthesis bodies (e.g., Cass Review context)
Highlight that the certainty of evidence underpinning hormonal pathways, especially in adolescents, is weaker than the strength of clinical recommendations implies.
How we got here
Medical masculinization with androgens dates to the mid-20th century, but formal protocols emerged with the Harry Benjamin International Gender Dysphoria Association (later WPATH), which published its first Standards of Care in 1979. The Endocrine Society issued its first gender-related guideline in 2009, substantially revised by Hembree and colleagues in 2017. WPATH SOC-8 (2022) marked a shift toward individualized, less gatekept care for adults and incorporated nonbinary identities and informed-consent pathways more explicitly than earlier editions.
- 1979Harry Benjamin association (later WPATH) publishes first Standards of Care
- 2009First Endocrine Society gender guideline
- 2017Endocrine Society guideline revised (Hembree et al.)
- 2022WPATH SOC-8 published; informed-consent and nonbinary care emphasized
- 2025US legal and regulatory environment around gender-affirming care shifts substantially, especially for minors
The people taking it
Primarily transmasculine adults (trans men) and a growing population of nonbinary people assigned female at birth who seek partial masculinization, sometimes via microdosing. Access expanded markedly with informed-consent and telehealth models in the 2010s-2020s.
Set against the alternatives
Assessment model: a mental-health professional evaluates and documents gender incongruence before hormones, historically the default and still common for adolescents and in some health systems. Informed-consent model: the prescribing clinician confirms capacity, reviews risks/benefits/uncertainties, and initiates testosterone without requiring a separate psychiatric referral, now common in US community and telehealth clinics. SOC-8 explicitly supports both, emphasizing individualized, capacity-based care for adults.
| Dimension | Gender-affirming T | Hypogonadism TRT | Practical note |
|---|---|---|---|
| Goal | Intentional virilization | Restore deficiency | Different intent |
| Baseline sex | Assigned female | Male | Distinct physiology |
| Target total T | ~320-1000 ng/dL | Mid-normal male range | Goal-guided |
| Diagnosis | Gender incongruence | Confirmed low T + symptoms | Not interchangeable |
| Governing framework | WPATH SOC-8; Endocrine Soc | Endocrine Soc; AUA | Specialty-specific |
| Fertility counseling | Before starting advised | Before starting advised | Both reversible-uncertain |
| Monitoring focus | T, hematocrit, virilization | T, hematocrit, PSA | Overlapping labs |
What we do not know
- What are the very-long-term (multi-decade) cardiovascular and oncologic outcomes of lifelong gender-affirming testosterone?
- How reversible is fertility after extended testosterone exposure?
- What are optimal regimens and outcomes for nonbinary microdosing?
What could change
Outcome registriesLong-term prospective cohorts to fill cardiovascular, bone, and oncologic data gapsIndividualized dosingLower-dose and nonbinary-tailored regimens for partial or non-binary virilization goalsFertility preservationBetter evidence on oocyte yield and reproductive outcomes after testosterone exposurePolicy volatilityShifting legal and regulatory landscape reshaping access and research funding
At a glance
- Goal
- Virilization to a typical male range, not deficiency correction
- Key guidelines
- WPATH SOC-8 (2022); Endocrine Society (Hembree 2017)
- Typical target total T
- ~320-1000 ng/dL (laboratory- and goal-dependent)
- Care models
- Assessment model vs informed-consent model
- Eligibility
- Persistent gender incongruence, capacity to consent, addressed comorbidities
- FDA label
- No testosterone product is FDA-labeled for this indication
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Masculinizing Hormone Therapy. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Children and teenagers. We have not checked what is known about younger people.
- What can go wrong. We have not written the risk line for this one. Read the safety section below rather than treating its absence as reassurance.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
WPATH Standards of Care Version 8 (SOC-8)2022
Internationally recognized framework; broadened informed-consent pathways and reduced rigid pre-hormone gatekeeping relative to prior versions
Endocrine Society Clinical Practice Guideline (Hembree et al.)2017
Endocrine treatment of gender-dysphoric/gender-incongruent persons; established diagnostic criteria, dosing, and monitoring framework, co-sponsored by WPATH